洛匹那韦/利托那韦治疗新型冠状病毒肺炎的临床效果

Clinical effect of lopinavir/ritonavir in the treatment of COVID-19

目的评价洛匹那韦/利托那韦治疗新型冠状病毒肺炎(COVID-19)的有效性。方法收集本院确诊的30例COVID-19患者的临床资料,根据治疗方式将其分为治疗组(n=19,应用洛匹那韦/利托那韦治疗)和对照组(n=11,未应用洛匹那韦/利托那韦治疗)。比较两组患者的临床指标及不良反应发生情况。结果两组患者体温恢复正常时间、症状消失时间、肺部影像学改善时间、住院时间比较,差异无统计学意义(P>0.05)。两组患者药物不良反应发生率比较,差异无统计学意义(P>0.05)。结论未发现洛匹那韦/利托那韦在改善症状、缩短肺部影像学改善时间及住院时间上优于其他抗病毒药物。

Objective To evaluate the efficacy of lopinavir/ritonavir in the treatment of COVID-19.Methods The clinical data of 30 COVID-19 patients confirmed in our hospital were collected and divided into treatment group(n=19,lopinavir/ritonavir treatment)and control group(n=11,no lopinavir/ritonavir treatment)according to treatment methods.The clinical indicators and adverse reactions were compared between the two groups.Results There were no significant differences in the time of body temperature returning to normal,symptom disappearance time,lung imaging improvement time and hospital stay between the two groups(P>0.05).There were no significant differences in the incidence of adverse drug reactions between the two groups(P>0.05).Conlusion It is not found that lopinavir/ritonavir is superior to other antiviral drugs in improving symptoms,shortening lung imaging improvement time and hospital stay.